The purpose of this study is to see if the study drug,amivantamab (also known as Rybrevant TM) is safe and useful for treating patients with Colorectal Cancer (CRC) when it is given alone or in addition to standard-of-care chemotherapies (mFOLFOX6 or FOLFIRI), as well as to find the best dose of amivantamab when given with chemotherapies. Amivantamab is an antibody made from a protein, designed to target and eliminate a specific harmful object in your body, in this case, a cancer cell. Amivantamab works by targeting a protein in your body known as epidermal growth factor receptor (EGFR), that...